Verastem, Inc.
VSTMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVerastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Valued at $909.3M, VSTM is a small-cap name in its sector. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Market Cap
$909.3M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-8.23
EPS (TTM)
$-2.45
EPS (Fwd)
$-1.22
ROE
-471.2%
ROA
-49.6%
Cash
$136.4M
Total Debt
$84.3M
Free CF
-$103.4M
52W Change
15.1%
Annual Financials
Cash vs Debt
Where VSTM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VSTM finished 44.63% above its 150-day moving average ($5.96) and 42.24% above its 200-day moving average ($6.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VSTM overbought or oversold?
At the October 20, 2026 close, VSTM's RSI(14) was 56.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $136.4M in cash comfortably exceeding the $84.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$103.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -471.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.6M (2022) to $30.9M (2025), reflecting a 1091% increase over the period.
The relatively low beta of 0.39 suggests VSTM is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Verastem, Inc. and its sector.